妊娠期UGT底物药物的生理药代动力学建模
本研究采用生理药代动力学(PBPK)模型,基于激素方程模拟妊娠期UGT1A1和UGT1A4的诱导,并假设UGT1A3、UGT2B7和UGT2B15不变,评估妊娠期UGT底物药物的药代动力学变化。结果显示82%的预测与观察比值在1.5倍误差范围内,UGT1A1、UGT1A4、UGT1A9和UGT2B7底物的PK变化被成功预测。结论提示整合妊娠期UGT表达/活性变化的PBPK模型可准确预测多数UGT代谢药物的PK,可能支持未来剂量调整。
要点
- 妊娠期UGT1A1和UGT1A4诱导用激素方程建模,UGT1A3、UGT2B7、UGT2B15假设不变。
- 82%的预测与观察比值在1.5倍误差内,UGT1A1、UGT1A4、UGT1A9、UGT2B7底物PK变化预测成功。
- PBPK模型可能支持妊娠期UGT底物药物未来剂量调整。
核心结论
- 整合妊娠期UGT1A1、UGT1A4和UGT1A9表达/活性变化或假设UGT2B7不变的PBPK模型,能准确预测多数UGT代谢药物的药代动力学。
研究设计与样本
- 研究采用生理药代动力学(PBPK)建模,评估妊娠期UGT底物药物的药代动力学变化。
- UGT1A1和UGT1A4的诱导使用基于激素的方程建模,考虑17β-雌二醇和孕酮的影响。
- UGT1A3、UGT2B7和UGT2B15因缺乏激素诱导表达的证据而被假设为不变。
主要发现
- 总体而言,妊娠人群预测与观察比值的82%在1.5倍误差范围内。
- P:NP比值如下:UGT1A1为88%,UGT1A4为50%,UGT1A9为100%,UGT2B7为100%,UGT2B15为25%。
- P:NP比值表明,妊娠人群中对UGT1A1、UGT1A4、UGT1A9和UGT2B7底物的PK变化被成功预测。
关键数值与推荐
- PBPK模型预测的准确性常用预测与观察比值评估,通常认为落在1.5倍误差内(即预测与观察PK参数的比值在1.5倍范围内)是可接受的。
临床怎么用
- 这些发现增进了对妊娠期II相代谢的理解,并可能在未来支持这些药物的剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: While pregnancy-related changes in phase I enzyme activity are well-documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5'-diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity. Physiologically based PK (PBPK) modelling was used to evaluate these changes in pregnant populations. METHODS: Induction of UGT1A1 and UGT1A4 in pregnancy was modelled using hormone-based equations, which account for the effects of 17β-oestradiol and progesterone. UGT1A3, UGT2B7 and UGT2B15 were assumed unchanged due to a lack of hormone-induced expression. The predicted-to-observed ratio is commonly used to assess the accuracy of PBPK models in predicting clinical data. PBPK model predictions are typically considered acceptable when they fall within a 1.5-fold error, defined as the ratio of the predicted to the observed PK parameter being within a 1.5-fold range. RESULTS: Overall, 82% of predicted to observed ratio of pregnant population were within 1.5-fold error. P:NP ratios were as follows: UGT1A1: 88%, UGT1A4: 50%, UGT1A9: 100%, UGT2B7: 100%, and UGT2B15: 25%. The P:NP ratio indicates that the PK changes in the pregnant population were successfully predicted for UGT1A1, UGT1A4, UGT1A9 and UGT2B7 substrates. CONCLUSIONS: p-PBPK models that incorporated pregnancy-induced changes in UGT1A1, UGT1A4 and UGT1A9 expression/activity, or assumed no change for UGT2B7, accurately predicted the pharmacokinetics of most UGT-metabolized drugs. These findings enhance our understanding of phase II metabolism during pregnancy and may support dose adjustment for those drugs in the future.
引用
- Saffaf W, van der Velde Y, Malik PRV, et al. Physiologically-based pharmacokinetic modelling of uridine 5'-diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women. Br J Clin Pharmacol. 2026. PMID: 41983686. doi:10.1002/bcp.70563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。